gene

ALPHA-SYNUCLEIN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALPHA-SYNUCLEIN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1769Connections

11Hypotheses

0Analyses

50Outgoing

50Incoming

6Experiments

0Debates

Summary

ALPHA-SYNUCLEIN is a gene implicated in neurodegeneration research. Key relationships include: associated with, activates, therapeutic target. Associated with ALS, Aging, Als. Connected to 529 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	ALPHA
Full Name	SYNUCLEIN
Chromosome	4q21.31
Protein Family	Synuclein family
Subcellular Localization	Presynaptic terminals, nucleus
Molecular Weight	14 kDa (140 aa)
Pathways	amyloid plaques, mTORC1, oxidative stress
UniProt ID	P37840
GeneCards	ALPHA
Human Protein Atlas	ALPHA
Direct oligomer binding	Anle138b binds to soluble oligomeric species, preventing their further growth and propagation
Membrane protection	The compound protects neuronal membranes from oligomer-induced pore formation
Associated Diseases	Aging, Als, Alzheimer, Alzheimer's Disease, Ataxia
Known Drugs/Compounds	DEXAMETHASONE, FINGOLIMOD, LITHIUM, proCTSD, RAPAMYCIN
Interactions	ACETYL-COA, ACLY, AGING, AKT, ALZHEIMER, ALZHEIMER DISEASE
KG Connections	1123 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🔮 Predicted Structure: ALPHA-SYNUCLEIN — AlphaFold P37840 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

modag

company · 1313 words

→

Pathway Diagram

graph TD
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| PARKINSON_S_DISEASE["PARKINSON'S DISEASE"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"activates"| INFLAMMATION["INFLAMMATION"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| ALS["ALS"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| SOD1["SOD1"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| DRD2["DRD2"]
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"associated"| AQP4["AQP4"]
    PARKIN["PARKIN"] -->|"regulates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    PARKINSON_S_DISEASE_1["PARKINSON'S DISEASE"] -->|"regulates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    MICROGLIA["MICROGLIA"] -->|"activates"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    PARKINSON_S_DISEASE_2["PARKINSON'S DISEASE"] -->|"associated"| ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"]
    style ALPHA_SYNUCLEIN fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1000)

Target	Relation	Type	Str
Parkinson	therapeutic_target	disease	1.00
Inflammation	activates	disease	1.00
Parkinson	associated_with	disease	1.00
Neurodegeneration	activates	disease	1.00
Parkinson	activates	disease	1.00
Parkinson's Disease	associated_with	disease	0.95
Lewy Body Formation	involved_in	process	0.95
Liquid-Liquid Phase Separation	involved_in	process	0.95
Synucleinopathies	causes	disease	0.95
Als	activates	disease	0.95
Mitochondrial Quality Control	modulates	pathway	0.95
DOPAMINERGIC NEURONS	contributes_to	cell_type	0.95
Parkinson's Disease	associated_with	disease	0.95
Lewy Bodies	component_of	structure	0.95
Lewy bodies	associated_with	phenotype	0.95
Synucleinopathies	causes	disease	0.95
Als	associated_with	disease	0.95
Multiple System Atrophy	involved_in	disease	0.95
Neurodegeneration	therapeutic_target	disease	0.95
Diffuse Lewy Body Disease	involved_in	disease	0.95
PARKINSON'S DISEASE	associated_with	gene	0.95
NEURON	associated_with	cell_type	0.95
Lewy Bodies	associated_with	biomarker	0.95
NLRP3	activates	protein	0.93
Dopaminergic Neurodegeneration	associated_with	process	0.93
MICROGLIA	activates	cell_type	0.92
Chaperone Proteins	correlates_with	protein	0.90
mTORC1	activates	pathway	0.90
dopaminergic neurons	causes	cell_type	0.90
autophagy	inhibits	process	0.90
KV1.3	upregulates	gene	0.90
toxic aggregation	causes	pathway	0.90
PARKINSON'S DISEASE	associated_with	disease	0.90
Neurodegeneration	causes	process	0.90
Parkinson'S Disease	associated_with	disease	0.90
STAT1	activates	gene	0.90
Lewy Body Formation	causes	process	0.90
Dopaminergic Neuronal Loss	contributes_to	phenotype	0.90
ACLY	activates	protein	0.90
Neuroinflammation	causes	process	0.90
Neurodegeneration	associated_with	process	0.90
STING	activates	protein	0.90
Parkinson's Disease	causes	disease	0.90
substantia nigra	causes	brain_region	0.90
NEUROINFLAMMATION	promotes	process	0.90
Parkinson	causes	disease	0.90
Autophagy	activates	pathway	0.90
NEURON	interacts_with	cell_type	0.86
Alzheimer	activates	disease	0.85
Inflammation	modulates	process	0.85

Incoming (769)

Source	Relation	Type	Str
entities-gt-02287	interacts_with	wiki	0.00
entities-overview	interacts_with	wiki	0.00
entities-snx5	interacts_with	wiki	0.00
entities-histone-deacetylase	interacts_with	wiki	0.00
entities-dna-methylation	interacts_with	wiki	0.00
entities-buntanetap	interacts_with	wiki	0.00
PARKINSON'S DISEASE	activates	gene	1.00
NEURODEGENERATION	activates	gene	1.00
SNCA	expresses	gene	1.00
PARKINSON'S DISEASE	associated_with	gene	1.00
PARKINSON	associated_with	gene	1.00
PARKINSON'S DISEASE	therapeutic_target	gene	1.00
PARKINSON	therapeutic_target	gene	1.00
Autophagy	downregulates	process	0.95
SNCA	encodes	gene	0.95
PARKIN	regulates	gene	0.95
SNCA	produces	gene	0.95
LAG3	interacts_with	protein	0.95
UB-312	targets	drug	0.90
DNAJB6	inhibits	protein	0.90
Prasinezumab	targets	drug	0.90
Cinpanemab	targets	drug	0.90
AFFITOPE PD01A	targets	drug	0.90
SDA-2026-04-01-gap-20260401-225155	investigates	analysis	0.90
LAG3	facilitates	protein	0.90
VINPOCETINE	attenuates	compound	0.90
TAU	interacts_with	protein	0.90
PINK1	phosphorylates	gene	0.90
LAG3	binds	protein	0.90
PARKINSON	activates	gene	0.90
NEURODEGENERATIVE DISEASES	associated_with	gene	0.90
INFLAMMATION	activates	gene	0.90
NEURON	activates	cell_type	0.86
NEURON	interacts_with	cell_type	0.86
APLP1	associated_with	protein	0.85
Autophagy	mediates	process	0.85
LRRK2	interacts_with	protein	0.85
ANTISENSE OLIGONUCLEOTIDE (ASO)	reduces_expression	compound	0.80
BAG3	mediates_clearance	gene	0.80
BAG3	mediates	gene	0.80
HSPG2	promotes_aggregation_of	gene	0.80
PINK1	associated_with	gene	0.80
NNMT	causes_aggregation_of	gene	0.80
VINPOCETINE	downregulates	compound	0.80
GBA	regulates	gene	0.80
MICROGLIA	associated_with	cell_type	0.80
proCTSD	targets	drug	0.80
TAU	associated_with	gene	0.80
NEURODEGENERATION	therapeutic_target	gene	0.80
PARKINSON	regulates	gene	0.80

Targeting Hypotheses (11)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S	0.822	neurodegeneration	What are the mechanisms by which gut mic
A downstream LRRK2-Rab10-JIP4 lysosomal stress loop promotes	0.680	neurodegeneration	Do pathogenic LRRK2 mutations amplify vo
Physiological SCFAs may reduce alpha-synuclein burden primar	0.650	neurodegeneration	Do physiological concentrations of SCFAs
H7: Enteric Nervous System Alpha-Synuclein Propagation Block	0.620	neurodegeneration	How does engineered C. butyricum cross t
CSF ApoE- and clusterin-rich lipoprotein particles stabilize	0.606	neurodegeneration	Which specific CSF molecular components

Ganglioside-rich extracellular vesicles preserve alpha-synuc	0.582	neurodegeneration	Which specific CSF molecular components
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali	0.571	neurodegeneration	Which cell types show the most significa
Direct neuronal HDAC inhibition is unlikely to mediate thera	0.560	neurodegeneration	Do physiological concentrations of SCFAs
Physiological SCFAs may worsen alpha-synuclein pathology thr	0.550	neurodegeneration	Do physiological concentrations of SCFAs
Sulfated glycans and metal-binding CSF proteins brace alpha-	0.489	neurodegeneration	Which specific CSF molecular components
Propionate may outperform acetate or butyrate at physiologic	0.440	neurodegeneration	Do physiological concentrations of SCFAs

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (6)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
Long-term perampanel treatment in A53T BAC-SNCA mice with PFF injectio	validation	Lewy body disease	0.950	A53T BAC-SNCA transgenic mice	proposed	N/A
Longitudinal TLR2 reporter gene study in α-synuclein mice	validation	Parkinson's disease	0.900	Thy1.2-α-synuclein transgenic	proposed	N/A
PFF uptake in primary hippocampal neurons with inhibitors	exploratory	Lewy body disease	0.900	mouse primary hippocampal neur	proposed	N/A
Dexamethasone treatment study in α-synuclein mice	validation	Parkinson's disease	0.850	Thy1.2-α-synuclein transgenic	proposed	N/A
PFF clearance kinetics in Snca knockout mice	validation	Lewy body disease	0.800	Snca knockout mice	proposed	N/A
TLR expression in α-synuclein overexpressing mice	validation	Parkinson's disease	0.800	mice overexpressing human α-sy	proposed	N/A

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391]	Lin Aung T, Aung YW, Shi X	Biomed Phys Eng Express	2026	1
A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647]	Tran HD, Shin MK, Yeo XY, Jung S, Junaid	Brain	2026	0
Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593]	Boyd RJ, Kho AR, McClymont SA, Loftus SK	Brain	2026	0
Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763]	Ueda J, Uemura N, Chang J, Hirato T, Ish	Mov Disord	2026	0
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889]	Fraser KB, Mirelman A, Mabrouk OS, Omer	J Parkinsons Dis	2026	0
Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116]	Wang Y, Lipton SA	J Neurochem	2026	0
SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927]	Statoulla E, Zafeiri M, Chalkiadaki K, V	NPJ Parkinsons Dis	2026	0
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496]	Panda SP, Saraswat N, Singh V	Neuroscience	2026	0
Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943]	Kabuta C, Hakuno F, Kataoka N, Takahashi	Neurochem Int	2026	0
An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745]	Asmi S, Krishnan A, Alexander SM, Mohame	Ageing Res Rev	2026	0
N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663]	Song P, Chen C, Franchini R, Duong B, Wa	J Clin Invest	2026	0
Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621]	["Singh R", "Maity P", "Jaiswal C"]	Neurochemistry international	2026	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning ALPHA-SYNUCLEIN in their description or question text